文献速递冠心病

减量普拉格雷与标准剂量氯吡格雷在老年急性冠脉综合征早期血运重建患者中的比较

Comparison of Reduced-Dose Prasugrel and Standard-Dose Clopidogrel in Elderly Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Revascularization.
PubMed 文献 · Circulation · 2018-02-19

该多中心随机开放标签盲终点试验纳入1443例年龄>74岁接受经皮冠状动脉介入治疗的急性冠脉综合征患者,比较普拉格雷5mg每日维持剂量与氯吡格雷75mg标准剂量。因预设中期分析显示疗效徒劳而提前终止,中位随访12个月时主要终点在两组间无差异(17% vs 16.6%,HR 1.007,95%CI 0.78-1.30,P=0.955)。

要点

  • 老年ACS行PCI患者中,减量普拉格雷5mg与标准氯吡格雷75mg的主要复合终点无差异。
  • 支架内血栓确定/可能发生率普拉格雷0.7% vs 氯吡格雷1.9%(OR 0.36,95%CI 0.13-1.00,P=0.06)。
  • BARC≥2型出血发生率普拉格雷4.1% vs 氯吡格雷2.7%(OR 1.52,95%CI 0.85-3.16,P=0.18)。

核心结论

  • 在>74岁急性冠脉综合征接受早期PCI的患者中,减量普拉格雷5mg与标准剂量氯吡格雷75mg在1年主要复合终点上无差异。
  • 研究因预设中期分析显示疗效徒劳而提前终止,结论需结合提前终止的背景解读。

研究设计与样本

  • 多中心、随机、开放标签、盲终点试验,比较普拉格雷5mg每日维持剂量与氯吡格雷75mg标准剂量。
  • 纳入1443例年龄>74岁、急性冠脉综合征接受经皮冠状动脉介入治疗的患者,40%为女性,平均年龄80岁,中位随访12个月。
  • 主要终点为1年内死亡、心肌梗死、致残性卒中及因心血管原因或出血再住院的复合终点,设计为证明普拉格雷5mg优于氯吡格雷75mg。

主要发现

  • 主要终点在普拉格雷组发生121例(17%),氯吡格雷组121例(16.6%),HR 1.007,95%CI 0.78-1.30,P=0.955。
  • 确定/可能支架内血栓发生率普拉格雷0.7% vs 氯吡格雷1.9%,OR 0.36,95%CI 0.13-1.00,P=0.06。
  • BARC 2型及以上出血发生率普拉格雷4.1% vs 氯吡格雷2.7%,OR 1.52,95%CI 0.85-3.16,P=0.18。

临床怎么用

  • 对于>74岁急性冠脉综合征行早期PCI的患者,减量普拉格雷5mg可作为与标准氯吡格雷75mg并列的个体化选择之一。
  • 临床决策需综合缺血与出血风险,并考虑本研究因疗效徒劳提前终止对结论稳健性的影响。

局限性

  • 研究因预设中期分析显示疗效徒劳而提前终止,可能影响统计效能与结论的稳健性。
  • 试验为开放标签设计,虽采用盲终点评估,但仍可能存在实施偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Elderly patients are at elevated risk of both ischemic and bleeding complications after an acute coronary syndrome and display higher on-clopidogrel platelet reactivity compared with younger patients. Prasugrel 5 mg provides more predictable platelet inhibition compared with clopidogrel in the elderly, suggesting the possibility of reducing ischemic events without increasing bleeding. METHODS: In a multicenter, randomized, open-label, blinded end point trial, we compared a once-daily maintenance dose of prasugrel 5 mg with the standard clopidogrel 75 mg in patients >74 years of age with acute coronary syndrome undergoing percutaneous coronary intervention. The primary end point was the composite of mortality, myocardial infarction, disabling stroke, and rehospitalization for cardiovascular causes or bleeding within 1 year. The study was designed to demonstrate superiority of prasugrel 5 mg over clopidogrel 75 mg. RESULTS: Enrollment was interrupted, according to prespecified criteria, after a planned interim analysis, when 1443 patients (40% women; mean age, 80 years) had been enrolled with a median follow-up of 12 months, because of futility for efficacy. The primary end point occurred in 121 patients (17%) with prasugrel and 121 (16.6%) with clopidogrel (hazard ratio, 1.007; 95% confidence interval, 0.78-1.30; P=0.955). Definite/probable stent thrombosis rates were 0.7% with prasugrel versus 1.9% with clopidogrel (odds ratio, 0.36; 95% confidence interval, 0.13-1.00; P=0.06). Bleeding Academic Research Consortium types 2 and greater rates were 4.1% with prasugrel versus 2.7% with clopidogrel (odds ratio, 1.52; 95% confidence interval, 0.85-3.16; P=0.18). CONCLUSIONS: The present study in elderly patients with acute coronary syndromes showed no difference in the primary end point between reduced-dose prasugrel and standard-dose clopidogrel. However, the study should be interpreted in light of the premature termination of the trial. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01777503.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Savonitto S, Ferri LA, Piatti L, et al. Comparison of Reduced-Dose Prasugrel and Standard-Dose Clopidogrel in Elderly Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Revascularization. Circulation. 2018. PMID: 29459361. doi:10.1161/CIRCULATIONAHA.117.032180

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。